GlassScriptPhysician profile
Mohamad H Raslan
NPI 1619938768
$1,721.34
in general payments reported to CMS, 2019-2025
14 companies · $422 in 2025
The $422 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.57 · 2021: $11.34 · 2022: $521 · 2023: $661 · 2024: $89.52 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $823 · Education: $199 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $822.80 |
| Education | $199.49 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $332.36 | 2021-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Regeneron Healthcare Solutions, INC. | $329.10 | 2022-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $207.99 | 2022-2025 | |
| Inspire Medical Systems, INC. | $139.97 | 2022 | |
| Genzyme Corporation | $138.59 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $127.44 | 2023 | Tezspire |
| Novo Nordisk INC | $125.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $86.61 | 2023 | Lifevest |
| Insmed, INC. | $49.86 | 2024-2025 | Brinsupri, Arikayce |
| Amgen INC. | $34.00 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $18.40 | 2025 | Opsynvi |
| Sunovion Pharmaceuticals INC. | $16.57 | 2020 | |
| Inogen, INC. | $15.46 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamad Raslan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.